Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gastromucin (also known as Gastromucoprotein or 胃膜素) is a biologic drug derived from porcine gastric mucosa, with mucoprotein as its primary active component. It functions as a mucosal protective agent by utilizing its strong adhesive properties to form a physical barrier on the inner wall of the digestive tract. This barrier specifically coats ulcerated areas, shielding damaged tissue from the corrosive effects of gastric acid and facilitating the healing process. Additionally, Gastromucin inhibits the enzymatic activity of pepsin, further reducing mucosal aggression. While it is long-established and approved for the treatment of gastric and duodenal ulcers, it is also being clinically investigated for its potential in managing inflammatory bowel diseases, including Crohn's disease and ulcerative colitis, often in combination with probiotic therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Gastromucin.